Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1989 1
1994 2
1995 2
1997 2
1999 2
2000 2
2001 1
2003 1
2004 1
2011 1
2014 2
2015 6
2016 5
2017 2
2018 3
2019 6
2020 6
2021 7
2022 3
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for heparin sodium in ay
Your search for heparin-sodium-n-ay retrieved no results
Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
Ay C, Pabinger I, Cohen AT. Ay C, et al. Thromb Haemost. 2017 Jan 26;117(2):219-230. doi: 10.1160/TH16-08-0615. Epub 2016 Nov 24. Thromb Haemost. 2017. PMID: 27882374 Review.
Evidence suggests that cancer itself is associated with a state of hypercoagulability, driven in part by the release of procoagulant factors, such as tissue factor, from malignant tissue as well as by inflammation-driven activation of endothelial cells, platelets, and leukocytes. …
Evidence suggests that cancer itself is associated with a state of hypercoagulability, driven in part by the release of procoagulant factors …
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Farge D, et al. Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7. Lancet Oncol. 2022. PMID: 35772465 Free PMC article. Review.
Abelacimab for Prevention of Venous Thromboembolism.
Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, Raskob GE, Weitz JI; ANT-005 TKA Investigators. Verhamme P, et al. N Engl J Med. 2021 Aug 12;385(7):609-617. doi: 10.1056/NEJMoa2105872. Epub 2021 Jul 19. N Engl J Med. 2021. PMID: 34297496 Clinical Trial.
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.
Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, Noble S, Sexton EA, Stenehjem D, Wiercioch W, Kahale LA, Alonso-Coello P. Lyman GH, et al. Blood Adv. 2021 Feb 23;5(4):927-974. doi: 10.1182/bloodadvances.2020003442. Blood Adv. 2021. PMID: 33570602 Free PMC article.
CONCLUSIONS: Strong recommendations include not using thromboprophylaxis in ambulatory patients receiving cancer chemotherapy at low risk of VTE and to use low-molecular-weight heparin (LMWH) for initial treatment of VTE in patients with cancer. ...
CONCLUSIONS: Strong recommendations include not using thromboprophylaxis in ambulatory patients receiving cancer chemotherapy at low risk of …
Catastrophic Antiphospholipid Syndrome.
Bitsadze V, Yakubova F, Khizroeva J, Lazarchuk A, Salnikova P, Vorobev A, Tretyakova M, Degtyareva N, Grigoreva K, Gashimova N, Kvaratskheliia M, Makatsariya N, Kudryavtseva E, Tomlenova A, Gris JC, Elalamy I, Ay C, Makatsariya A. Bitsadze V, et al. Int J Mol Sci. 2024 Jan 4;25(1):668. doi: 10.3390/ijms25010668. Int J Mol Sci. 2024. PMID: 38203837 Free PMC article. Review.
Reduced Ischemic Lesion Growth with Heparin in Acute Ischemic Stroke.
Rocha EA, Ji R, Ay H, Li Z, Arsava EM, Silva GS, Sorensen AG, Wu O, Singhal AB. Rocha EA, et al. J Stroke Cerebrovasc Dis. 2019 Jun;28(6):1500-1508. doi: 10.1016/j.jstrokecerebrovasdis.2019.03.016. Epub 2019 Mar 29. J Stroke Cerebrovasc Dis. 2019. PMID: 30935810 Free PMC article.
OBJECTIVE: The role of heparin in acute ischemic stroke is controversial. We investigated the effect of heparin on ischemic lesion growth. ...Heparin treatment did not predict functional outcome at discharge or 90 days. ...
OBJECTIVE: The role of heparin in acute ischemic stroke is controversial. We investigated the effect of heparin on ischemic le …
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Farge D, et al. Lancet Oncol. 2019 Oct;20(10):e566-e581. doi: 10.1016/S1470-2045(19)30336-5. Epub 2019 Sep 3. Lancet Oncol. 2019. PMID: 31492632
Results from head-to-head clinical trials that compared direct oral anticoagulant with low-molecular-weight heparin are also summarised, along with new evidence for the treatment and prophylaxis of VTE in patients with cancer....
Results from head-to-head clinical trials that compared direct oral anticoagulant with low-molecular-weight heparin are also summaris …
Unanswered questions in cancer-associated thrombosis.
Sanfilippo KM, Moik F, Candeloro M, Ay C, Di Nisio M, Lee AYY. Sanfilippo KM, et al. Br J Haematol. 2022 Sep;198(5):812-825. doi: 10.1111/bjh.18276. Epub 2022 May 25. Br J Haematol. 2022. PMID: 35611985 Review.
The effect of intraurethral heparin on inflammation and spongiofibrosis in a rat model of experimentally induced urethral trauma.
Hızlı F, Demirci A, Benzer E, Hızlı H, Başar H. Hızlı F, et al. Int Urol Nephrol. 2023 Jun;55(6):1421-1426. doi: 10.1007/s11255-023-03613-1. Epub 2023 Apr 28. Int Urol Nephrol. 2023. PMID: 37115457
RESULTS: A statistically significant difference was found between the three groups (control, heparin, and heparin + saline) in the histopathological status of spongiofibrosis, inflammation, and congestion, respectively (P = 0.0001, P = 0.002, P = 0.0001). Severe spo …
RESULTS: A statistically significant difference was found between the three groups (control, heparin, and heparin + saline) in …
Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.
Field TS, Dizonno V, Almekhlafi MA, Bala F, Alhabli I, Wong H, Norena M, Villaluna MK, King-Azote P, Ratnaweera N, Mancini S, Van Gaal SC, Wilson LK, Graham BR, Sposato LA, Blacquiere D, Dewar BM, Boulos MI, Buck BH, Odier C, Perera KS, Pikula A, Tkach A, Medvedev G, Canfield C, Mortenson WB, Nadeau JO, Alshimemeri S, Benavente OR, Demchuk AM, Dowlatshahi D, Lanthier S, Lee AYY, Mandzia J, Suryanarayan D, Weitz JI, Hill MD; SECRET Investigators. Field TS, et al. Stroke. 2023 Nov;54(11):2724-2736. doi: 10.1161/STROKEAHA.123.044113. Epub 2023 Sep 7. Stroke. 2023. PMID: 37675613 Free article. Clinical Trial.
Participants were aged 18 years, within 14 days of a new diagnosis of symptomatic CVT, and suitable for oral anticoagulation; they were randomized to receive rivaroxaban 20 mg daily, or standard-of-care anticoagulation (warfarin, target international normalized ratio, 2.0-3.0, or …
Participants were aged 18 years, within 14 days of a new diagnosis of symptomatic CVT, and suitable for oral anticoagulation; they were rand …
61 results